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Nephritis is the most frequent severe manifestation of
anti-neutrophil cytoplasm antibody associated (ANCA)
systemic vasculitis (AASV) and systemic lupus erythematosus
(SLE) and carries substantial morbidity. Although
immunosuppressive medications and glucocorticoids are
effective at inducing remission, patients still suffer from high
relapse rates and experience significant treatment-related
toxicity. Rituximab (RTX), a chimeric antibody directed against
CD20, found on B lymphocytes, shows potential as a treatment
for both AASV and SLE. Although direct comparisons with
standard therapies are currently unavailable, patients in
several studies of refractory and relapsing disease have achieved
a remission despite the failure of standard therapies. These
reports are supported by several lines of experimental
evidence that underlie the rationale for using targeted B-cell
therapies and have improved our understanding of the
pathogenesis of these complex diseases. Future randomized
control trials and long-term follow-up studies are required to
confirm the role of RTX and other B-cell targeting therapies
in AASV and SLE.
Kidney International (2007) 72, 676–682; doi:10.1038/sj.ki.5002395;
published online 4 July 2007
KEYWORDS: vasculitis; systemic lupus erythematosus; lupus nephritis;
rituximab; monocolonal antibody
Anti-neutrophil cytoplasm antibody (ANCA) associated
systemic vasculitis (AASV) and systemic lupus erythematosus
(SLE) with nephritis are characterized as small vessel
inflammatory diseases with multisystem involvement and
autoantibody production. Both diseases have a dismal
natural history with 5-year survival rates between 0 and
20% left untreated and end-stage renal disease, a common
complication.
The current accepted standard of care for both diseases is
glucocorticoids and an immunosuppressive, most often
cyclophosphamide. This has improved 5-year survival rates
to between 70 and 90%. Despite this remarkable improve-
ment in survival, up to 20% of patients with these diseases do
not respond to standard drug regimens and of those who do
respond, up to 50% have relapses of their disease. This is
further complicated by the toxicity of both glucocorticoids
and cyclophosphamide. In particular, high infection rates,
gonadal toxicity, and malignancy are of concern. Given these
factors, newer treatments are clearly indicated and ideally will
provide longer lasting remission and a less toxic adverse event
profile.
B-cell depleting therapies, such as rituximab (RTX), have
been considered as a potential treatment for AASV and SLE.
We will review the rationale for this treatment, the current
state of evidence for its efficacy and toxicity, and highlight
areas for future research with B-cell depleting therapies and
other B-cell targeted therapies.
THE RATIONALE FOR TARGETED B-CELL THERAPY
B cells occupy a central role in the normal immune
system (Figure 1). Within the context of autoimmunity,
T-cell autoreactivity, an important component of inflam-
matory autoimmune diseases, is supported by B cells,1
either through antigen presentation or co-stimulation.
Unlike dendritic cells, B cells are antigen specific and capable
of clonal expansion amplifying immune responses.
T-cell-derived cytokines (e.g. BLyS and APRIL) modify
B-cell activity via surface receptors (e.g. TACI). Following
activation and maturation, B cells traffic to sites of
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inflammation and recruit inflammatory cells or differentiate
to plasmablasts. Thus, B-cell activity may be influenced
by targeting B-cell stimulatory cytokines, B-cell surface
receptors, or via B-cell depletion. Although plasma cells
are not affected directly by B-cell-targeted therapies,
depleting B cells, which may differentiate into autoanti-
body-producing plasma cells or alter circulating plasma-
blast function, make B cells a rational target.2 Thus, while B-
cell depleting therapy specifically removes B cells and not
other cells of the immune system, the effects of B-cell
depletion or modifying B-cell activity may have widespread
immunologic effects.
Specific evidence for the roles of B cells in AASV and
SLE can also be found. In AASV, abnormal B-cell clusters
adjacent to proteinase 3 (PR3)-ANCA-positive cells and
plasma cells have been observed in nasal biopsies.3 Addi-
tionally, the regulation of T lymphocytes, known to be
important in AASV, is interdependent on B-cell function.4,5
In SLE, abnormalities of B-cell interactions with antigen-
presenting cells and B-cell hyperactivity may drive the
autoimmune process.6,7
THE EVIDENCE FOR RITUXIMAB
RTX is an IgG1 k mouse/human chimeric monoclonal
antibody directed against the B-cell surface receptor CD20. It
was licensed in 1997 for use in non-Hodgkin lymphoma and
over 950 000 patients have now been treated with RTX for
this indication. RTX is now also licensed for rheumatoid
arthritis. CD20 is a cell surface receptor stably expressed
on immature and mature B cells but not on plasma
cells. Binding of RTX to CD20 induces apoptosis, anti-
body-dependent cellular cytotoxicity, and complement-de-
pendent cytotoxicity. In SLE, the efficacy of B-cell depletion
by RTX may depend in part on the FcgRIIIa genotype of
the patient.8
Patient selection and basis for studies
As an experimental therapy, published reports of RTX use in
AASV and SLE are limited to retrospective case series and
small prospective open-label trials of patients treated with
RTX for refractory or frequently relapsing disease. The
clinical experience with RTX in both AASV and SLE is much
more extensive than the published experience and the
probability of a positive publication bias must be considered
in the review of this body of literature. Additionally, these
studies generally occur in referral centers with experience in
refractory AASV/SLE and the administration of immuno-
therapies. Furthermore, the effect of RTX with respect to
long-term outcomes, sustained remissions of disease, and the
prevention of hard end points, such as death and renal
failure, are not addressed in the current body of literature.
Lastly, all the studies mentioned below included patients with
renal involvement but not necessarily rapidly progressive
nephritis or severe renal dysfunction. In SLE studies, only
two are dedicated to proliferative lupus nephritis (PLN).9,10
With these caveats in mind, the results of RTX studies in
these difficult to treat patients have encouraging biological
and clinical results. The results of published case series
and open-label trials are summarized for AASV and SLE in
Tables 1 and 2, respectively.
Therapeutic protocols
Experience with RTX in lymphoma has standardized four
weekly doses of 375 mg/m2, while experience in rheumatoid
arthritis has developed a protocol of two 1000 mg doses
biweekly. Protocols for administering the RTX to patients
with AASV and SLE have varied between ‘lymphoma’ doses
and ‘rheumatoid’ doses. One small dose-escalating study
varied the total dose given to patients with SLE between 100
and 1500 mg/m2,11 and one study of AASV used a dose of
375 mg/m2 every 4 weeks.12 No obvious differences in either
efficacy or toxicity have been demonstrated between the
lymphoma and rheumatoid protocols although direct
comparisons are lacking. The majority of studies cited below
utilized traditional ‘lymphoma’ dosing protocols with a few
using ‘rheumatoid’ protocols.
There is little guidance on the use of RTX alone, with
glucocorticoids or with glucocorticoids and immunosuppressive
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Figure 1 | Central role B cells in the development of autoimmune
target organ damage. (1) Auto-antigen stimulation of T cells by
antigen presenting cells (APC) or B cells via MHC/antigen–T-cell
receptor interactions in conjunction with co-stimulation by
CD80(86)-CD28 or CD40-CD40L interactions; (2) T-cell secretion of
cytokines such as BLyS or APRIL, which, via cell surface receptors
like TACI, induce B-cell maturation and differentiation to plasma cells;
(3) B-cell secretion of cytokines such as interleukin-10 and interferon-a
induce differentiation of APC to monocytes; (4) B-cell clonal
proliferation after exposure to autoantigens; (5) Neutrophil activation
and recruitment in peripheral tissues by cytokines; (6) B-cell
differentiation to autoantibody-producing plasma cells.
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Table 1 | Summary of published reports of rituximab use in anti-neutrophil cytoplasm antibody associated systemic vasculitis
Study
No. of
patients (no.
of nephritis) Dose of RTX
Concomitant
treatments
Remission
(nephritis)
B-cell
depletion ANCA serology Relapse
Aries (2006) 8 (2) 375 mg/m2 every
4 weeks 4
CYC, MMF, MTX 2/8 (1/2) 8/8 0/8 became negative;
no significant change in
titer
NR
GC
Eriksson
(2005)
9 (7) 500 mg weekly 4 or MMF, AZA, CYC 8/9 complete,
1/9 partial (7/7)
9/9 0/7 became negative;
no significant change in
titer
2 (12 and 13
months)500 mg every other
week 2
GC
Keogh (2005) 11 (4) 375 mg/m2 weekly 4 PLEX for
nephritis
10/11
complete, 1/11
partial (4/4)
11/11 8/11 became negative;
all decreased titer
2 (7 and 12
months)
GC
Keogh (2006) 10 (7) 375 mg/m2 weekly 4 GC 10/10 complete
(7/7)
10/10 6/10 became negative;
all decreased titer
1 (9 months)
Omdal (2005) 3 (3) 375 mg/m2 weekly 4 NR 3/3 complete 3/3 0/3 became negative;
all decreased titer
3/3 (8, 13,
and 15
months)
Smith (2006) 11 (6) 375 mg/m2 weekly 4; MMF 9/11 complete,
1/11 partial
11/11 6/10 became negative;
all decreased titer
6/10 (median
16.5 months)1 g every other
week 2 for
retreatment
GC
Stasi (2006) 10 (6) 375 mg/m2 weekly 4 GC 9/10 complete,
1/10 partial
10/10 8/10 became negative;
all decreased titer
3/10 (12, 16,
and 24
months)
ANCA, anti-neutrophil cytoplasm antibody; AZA, azathioprine; CYC, cyclophosphamide; GC, glucocorticoids; MMF, mycophenolate mofetil; MTX, methotrexate; NR, not
reported; PLEX, plasma exchange; RTX, rituximab.
Table 2 | Summary of published reports of rituximab use in systemic lupus erythematosus
Study
No. of
patients (no.
of nephritis) Dose of RTX
Concomitant
treatments
Remission
(nephritis)
B-cell
depletion Anti-dsDNA serology Relapse
Gottenberg 13 (4) 375 mg/m2 every
4 weeks 1–4
NR 7/13 complete,
2/13 partial (2/4)
NR 4 became negative;
2 decreased; 3 no
change, and 2
increased; 2 missing
data
2/9 (9 and 15
months)
Leandro 24 (17) 500 mg every other
week 2 or
CYC
GC
24/24 improved
(17/17 improved)
23/24 Statistically significant
decrease reported
7/24 (timing
NR)
1000 mg every other
week 2
Looney 18 (6) 100 mg/m2 1 or
375 mg/m2 1 or
375 mg/m2 weekly 4
AZA, MTX, HCQ 13/18 improved
(4/6 improved)
11/17 No significant change
reported
NR (4/11 with
improvement
subsequently
worsened)
GC
Sfikakis 10 (10) 375 mg/m2 weekly 4 GC 5/10 complete,
3/10 partial (8/10)
9/10 Statistically significant
decrease reported
3/8 (5, 5, and 8
months)
Smith 11 (6) 375 mg/m2 weekly 4 MMF, AZA GC 6/11 complete,
5/11 partial (6/6)
11/11 No significant change
reported
7/11 (median
12 months)
Vigna-Perez 22 (22) 500–1000 mg every
other week 2
MMF, MTX,
AZA
GC
5/22 complete,
7/22 partial, 18/22
improved (12/22)
20/22 No significant change
reported
NR
ANCA, anti-neutrophil cytoplasm antibody; AZA, azathioprine; CYC, cyclophosphamide; GC, glucocorticoids; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil;
MTX, methotrexate; NR, not reported; RTX, rituximab.
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medications. The majority of studies considered here used
concomitant glucocorticoids and immunosuppressive med-
ications.10–15 Following treatment with RTX, glucocorticoids
were generally tapered as allowed by reductions in clinical
symptoms. For patients with AASV and renal involvement, a
single study systematically employed concomitant plasma
exchange without the use of other immunosuppressive
medications.16
Immunologic response
Studies of patients with AASV treated with RTX demonstrate
peripheral B-cell depletion universally within 4 weeks of
treatment.13,15–19 The return of peripheral B cells was
generally noted to occur within 6–12 months of treatment.
ANCA titers were significantly reduced in most studies and
dropped below the lower limit of detection in 60–80% of
patients in four studies.15–17,19 In two studies, however, no
significant changes in ANCA titers were noted despite
peripheral B-cell depletion.12,13 Reductions in ANCA titers
were slower than B-cell depletion, as expected, and generally
ANCA did not return or begin to rise again until after
peripheral B cells began reconstitution.
In contrast to the AASV experience, peripheral B-cell
depletion is expected but does not occur universally in
patients with SLE treated with RTX. No general association
between the RTX protocol (‘lymphoma’ vs ‘rheumatoid’)
or patient characteristics and the likelihood of peripheral
B-cell depletion are apparent. Peripheral B cells returned
to measurable levels between 1 and 17 months after
treatment.9,14,15,20 Unlike the autoantibodies of AASV,
RTX did not have consistent effects on anti-dsDNA
antibodies. Two studies show significant reductions in
anti-dsDNA antibodies,9,14 one of which was specifically
in patients with PLN.9 All other studies showed in-
consistent changes in anti-dsDNA antibody titers
between patients and no significant overall effect.10,11,15,20
However, sub-studies specifically aimed at determining
antibody responses to RTX frequently show a reduction
in autoantibody titers.9,21–23 A similar change in anti-
microbial antibody titers was not demonstrated; a finding
which suggests that the turn-over of plasma cells producing
autoantibodies is more rapid than those producing microbial
antibodies and thus more sensitive to the effects of
B-cell depletion.21 Complement levels generally improved
in patients.
Several studies have also explored the mechanistic
immunologic effects of RTX in patients with SLE. Anolik
et al.24 demonstrated that RTX reversed several abnormalities
of B-cell homeostasis and reduced the number of auto-
reactive memory B cells up to 1 year after treatment with
RTX. Downregulation of CD40 and CD80, co-stimulatory
molecules for T lymphocytes, after RTX have also been
demonstrated and imply possible modification of T lympho-
cyte function after B-cell depletion. In patients with PLN,
RTX has been shown to decrease T-helper cells and improve
T-regulatory cell function.9,10
Clinical response: induction
Patients generally experienced a remission of disease after
treatment with RTX in these studies. All patients in five out
of seven studies with AASV treated with RTX had at least a
partial remission. In the six studies with favorable responses,
complete remission occurred in 50 out of 54 patients
reported.13,15–19 These patients included 33 with renal
involvement of which two were on dialysis at the time of
treatment. Remission was obtained by 6 months after
treatment in all of these cases. Inflammatory markers such
as erythrocyte sedimentation rate and C-reactive protein were
noted to decrease in parallel with clinical activity. In a single
study of eight patients, only three experienced a reduction of
disease activity, one of whom had renal involvement.12 The
disease of patients in this study was largely characterized by
refractory retro-orbital granulomas, an uncommon manifes-
tation in patients in other studies and a different dosing
schedule of RTX.
Four studies of SLE including 64 patients,11,14,15,20 half of
which had PLN, and two studies of 32 patients specifically
with PLN9,10 all demonstrate some improvement in SLE
activity. Complete responses did not occur as commonly as in
AASV. All six studies, reporting on 96 patients, reported
almost all patients had some improvement. Of the four
studies reporting complete and partial remissions,9,10,15,20
within 1–8 months of treatment, 23 of 56 patients had
complete remissions and an additional 17 had partial
remissions. In those patients with PLN, proteinuria was
consistently decreased after treatment with RTX although the
course of resolution was sometimes prolonged.11,15 One
study also demonstrated the largest improvements were
primarily experienced in musculoskeletal and dermatologic
systems.11 A case series of lupus nephritis proven refractory
to cyclophosphamide treatment by biopsy, however, showed
improvement with the addition of RTX to cyclophosphamide
on subsequent biopsies.25 These generally positive reports in
adult patients are also supported by reports in children with
severe manifestations of SLE.26
Clinical response: relapse and retreatment
Relapse after treatment with RTX remains a major concern in
both AASV and SLE. In AASV studies, 20 out of 44 patients
had a relapse Relapses occurred between 12 and 24 months
after treatment. Rising ANCA titers frequently preceded
clinical relapses and all but one relapse occurred in patients
with at least partial reconstitution of peripheral B cells.15 In
studies of patients with SLE treated with RTX, between 15
and 65% of patients experienced a relapse between 6 and 23
months after treatment (most commonly at approximately
1 year after treatment).9,15,20 In all but one case, relapse
occurred after the reconstitution of peripheral B lymphocytes.15
Retreatment with RTX is only reported infrequently
and its effects and associated toxicity remain largely
unknown. However, retreatment of both AASV and
SLE with RTX generally appeared efficacious although
the duration of B-cell depletion may be slightly shorter.15
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In addition, repeated RTX infusions may be associated with a
higher risk of infusion reactions and the development of
human anti-chimeric antibodies (HACA) (see Toxicity and
side effects below).27
Toxicity and side effects
Toxicity data specific to AASV and SLE is still limited. In
related autoimmune inflammatory phenotypes such as
rheumatoid arthritis, over 300 patients have been treated in
the context of clinical trials with RTX and it was very well
tolerated in the short-term data currently available.28 In the
above studies in AASV and SLE, serious infusion reactions
were rare. Similarly, serious infections were rarely reported in
either condition but there has been concern raised as to the
role of rituximab in the rare development of unusual
infections, such as progressive multifocal leukoencephalo-
pathy, in patients with SLE.29 The relative contribution of
RTX and previous or ongoing immunosuppressive medica-
tions is also unknown. Additionally, many studies of RTX, in
AASV, SLE, and rheumatoid arthritis, demonstrate reduc-
tions in circulating immunoglobulins ranging from mild to
quite severe.11,15–17,19 Additionally, infective risks may be
increased due to an impaired secondary humoral response
(e.g. immunizations).30
There has also been concern over the use of RTX
repeatedly due to the antigenicity of its murine component.
This may increase the chances of serum sickness or
hypersensitivity reactions.31 Repeat doses may also induce
high levels of human antibodies directed against RTX, which
could neutralize the actions of RTX. Although HACA are
commonly found in patients treated with RTX, their clinical
significance is poorly understood. There are cases where the
antibodies interfere with the efficacy of RTX, particularly in
high titer,14,27 but the majority of patients with HACA still
have a clinical response to at least two repeated doses.
Repeated doses beyond this are not yet well studied.
Differences in HACA assay techniques may contribute to
the uncertainties about what levels of HACA are clinically
relevant.
The occurrence of other immunologic phenomena after
treatment with RTX has also been reported. These include
coagulopathies32,33 and RTX-induced cutaneous vasculi-
tides.34,35 These occurrences are still the subject of case
reports and the nature and magnitude of the association of
new autoimmune diseases after treatment with RTX is, as yet,
unknown.
FUTURE DIRECTIONS FOR TARGETED B-CELL THERAPIES IN
VASCULITIS AND LUPUS
Several randomized controlled trials are now underway
(short titles: RITUXVAS and RAVE in AASV and EXPLORER
and LUNAR in SLE – clinicaltrials.gov), testing the efficacy
of RTX against traditional therapies in both AASV and
SLE. These trials are designed to show the efficacy of RTX
as an induction agent either alone or in conjunction with
a reduced dose of cyclophosphamide. As such, the ability
of RTX to prevent future relapses, end-stage renal disease,
or death will not be directly answered by these trials.
Additionally, the question as to whether RTX should be
used as an adjuvant or an alternative to traditional
immunosuppressive medications will not be directly an-
swered although differences in trial designs may give
important clues to this topic. Although the trials currently
underway will provide very important information regarding
the efficacy and short-term safety of RTX in these diseases,
longer term studies focusing on hard clinical end points will
still be warranted.
Should RTX prove both as more effective and less toxic
than drugs such as IV cyclophosphamide, in the ongoing
clinical trials, there will still be several questions as to its
use. These include the use of RTX as a chronic immuno-
suppressive rather than an induction drug and the role
and timing of re-dosing and the role of biomarkers in re-
dosing. Additionally, the use of RTX in related disorders
such as anti-phospholipid antibody syndromes,36,37 CNS
lupus,38 and non-ANCA vasculitides, the use of B-cell
depleting therapy in primary glomerular diseases, and
the pharmacodynamic and pharmacokinetic impacts of
heavy proteinuria and low glomerular filtration rate remain
to be determined.
The goals of all RTX, and of new therapies for AASV
and SLE in general, are invariant: to improve the quality
and length of life of patients while limiting treatment-related
toxicity. An important component of this is the ability of
new therapies to reduce patients’ exposure to immunosup-
pressive medications and glucocorticoids. A durable remis-
sion in the absence of glucocorticoids appears unlikely with
RTX, given current experiences with high rates of late
relapses in both AASV and SLE. Whether this can be
overcome with more effective B-cell targeted therapies
remains to be seen but there are several potential therapies
in development. New B-cell depleting medications, such as
the humanized anti-CD20 antibodies, ocrelizumab, and
ofatumumab, may induce more complete and longer lasting
B-cell depletion as well as alter the proportions of
B-cell death that occur through complement-dependent,
apoptotic, and antibody-dependent mechanisms. In addition
to these, non-depleting, targeted, B-cell therapies are
under development. These include anti-BLyS (belimumab)
and anti-APRIL which inhibit the interactions of B cells
with T cells and are involved in B-cell survival and
maturation in both the lymphoid tissues and periphery.
Preclinical studies have already demonstrated that tissue B-
cell depletion may be enhanced by the addition of anti-BLyS
to the administration of RTX,39 and preclinical and clinical
trials of these agents are beginning in other diseases. Cell
surface receptors have also been targeted with TACI-Ig
(atacicept) in early clinical trials for SLE.
CONCLUSION
While studies of RTX for AASV and SLE are limited to case
reports/series and small clinical trials, it shows promise as a
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new treatment for these difficult to manage diseases. The
available data suggest that RTX appears safe and in the hands
of experienced centers may be considered for the treatment of
refractory AASV or SLE. More widespread use of RTX for
these indications requires efficacy to be demonstrated in
randomized control trials, several of which are underway.
However, several issues regarding the use of RTX will remain
even after the completion of these trials. These issues include:
RTX as initial therapy for these diseases has not yet been
investigated; the dosing regimen and need for concomitant
therapies must be explored; and the impact of RTX on
long-term clinical outcomes, such as end-stage renal disease
and death and adverse events. In the future, drugs such as
RTX may prove to not only increase the number of
medications available for the treatment of these disorders
but also provide a more durable response and a novel method
for exploring the pathogenesis of AASV and SLE. Should
RTX prove efficacious in these diseases, other B-cell-targeted
therapies may also prove useful for these difficult to treat
diseases.
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